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Recently, the numbers of patients with non-alcoholic fatty liver disease (NAFLD) and
non-alcoholic steatohepatitis (NASH) have increased worldwide. NAFLD and NASH are
known as risk factors for liver cirrhosis and hepatocellular carcinoma. Because many
factors can promote the progression of NAFLD and NASH, the treatment of these patients
involves various strategies. Thus, it is desired that drugs for patients with NAFLD and
NASH should be developed more easily and rapidly using cultures of primary hepatocytes.
However, it is difficult to use hepatocytes as a tool for drug screening, because these cells
cannot be functionally maintained in culture. Thus, in this study, we sought to examine
whether induced hepatocyte-like (iHep) cells, which were directly induced from mouse
dermal fibroblasts by infection with a retrovirus expressing Hnf4α and Foxa3, possess the
potential for lipid metabolism, similar to hepatocytes. Our data showed that iHep cells
were capable of synthesizing lipids from a cis-unsaturated fatty acid, a trans-unsaturated
fatty acid, and a saturated fatty acid, accumulating the synthesized lipids in cellular
vesicles, and secreting the lipids into the culture medium. Moreover, the lipid synthesis
in iHep cells was significantly inhibited in cultures with lipid metabolism improvers. These
results demonstrate that iHep cells could be useful not only for screening of drugs for
patients with NAFLD and NASH, but also for elucidation of the mechanisms underlying
hereditary lipid metabolism disorders, as an alternative to hepatocytes.
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INTRODUCTION
The recent increase of the number of patients with non-alcoholic
fatty liver disease (NAFLD), which often develops through
obesity and lipid metabolism disorders, is an issue that has
become problematic in liver diseases (Vuppalanchi and Chalasani,
2009). NAFLD can be characterized into simple steatosis and
non-alcoholic steatohepatitis (NASH). In particular, NASH is
associated with the risk of inducing not only liver cirrhosis and
hepatocellular carcinoma, but also heart diseases (Hashimoto
et al., 2009; Vuppalanchi and Chalasani, 2009). In general, as
the cause of NASH developing from fatty liver disease, a “two-
hit hypothesis” has been proposed (Day and James, 1998). The
first hit is the onset of steatohepatitis, which is induced as a
result of cellular lipid accumulation and steatosis. The second hit
includes activation of inflammatory cytokines and hepatic oxida-
tive stress (Day and James, 1998; Dowman et al., 2010). As the
current therapeutic drugs for NASH, insulin-resistance improvers
and antioxidants are frequently used. However, there are many
factors that can promote the progression of NAFLD and NASH.
Therefore, if we are able to develop many drugs for patients
with NAFLD and NASH more easily and rapidly it will become
possible to beat the causative factors of these diseases specifically.
Ideally, primary hepatocytes should be used in the screening
of drugs for patients with liver diseases. However, it is difficult
to maintain the function of hepatocytes in culture. Thus, liver
cancer cell lines are often substituted for hepatocytes, although
the nature of these cell lines differs from that of normal hep-
atocytes. To obtain functional hepatocytes for the screening of
drugs, hepatocyte-like cells can be induced from embryonic
stem (ES) cells and induced pluripotent stem (iPS) cells (Basma
et al., 2009; Rashid et al., 2010; Si-Tayeb et al., 2010; Cayo
et al., 2012; Choi et al., 2013). Moreover, recent advances in the
induction of cellular reprogramming have enabled the genera-
tion of hepatocyte-like cells directly from fibroblasts, which is
termed “direct reprogramming” (Huang et al., 2011; Sekiya and
Suzuki, 2011). In our previous paper, we reported that three
specific combinations of two transcription factors, comprising
Hnf4α plus Foxa1, Foxa2, or Foxa3, can be used to convert
mouse fibroblasts into hepatocyte-like cells (Sekiya and Suzuki,
2011). The induced hepatocyte-like (iHep) cells exhibited mul-
tiple hepatocyte-specific functions and restored hepatic tissues
after transplantation. Thus, it is expected that iHep cells could
be used for developing regenerative therapies and examining the
pharmacological effects of drugs. Although iHep cells may be use-
ful in the screening of drugs for patients with NAFLD and NASH,
the capability for lipid metabolism in iHep cells remains to be
clarified. Thus, in this study, we examined whether iHep cells pos-
sess the potential for lipidmetabolism, similar to hepatocytes, and
further attempted to clarify whether iHep cells could be useful
not only for the screening of drugs but also for the progression
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of basic research for patients with liver diseases involving lipid
metabolism.
MATERIALS AND METHODS
GENERATION OF iHEP CELLS
We generated iHep cells from mouse dermal fibroblasts (MDFs)
and conducted co-immunofluorescence staining of albumin with
E-cadherin, as described previously (Sekiya and Suzuki, 2011).
Some modifications that were added to the methods are specif-
ically described below. In the preparation of MDFs, we incubated
small pieces of skin tissue obtained from C57BL/6 adult mice
(8–10 weeks of age) in Hanks’ balanced salt solution contain-
ing 0.05% collagenase (Wako, Osaka, Japan) and 0.01% trypsin
inhibitor (Nacalai Tesque, Kyoto, Japan) for 20min at 37◦C. The
treated tissues were then collected by centrifugation (200 g for
3min), plated on gelatin-coated six-well plates, and grown until
expandedMDFs reached confluency. In the production of recom-
binant retroviruses, we used PLAT-E cells (Morita et al., 2000) for
transfection of plasmid DNA. In this study, we used iHep cells at
passage 9–12 for examination.
INDUCTION OF LIPID SYNTHESIS AND SECRETION
To induce lipid synthesis, iHep cells were cultured in our hepato-
medium (Sekiya and Suzuki, 2011) containing 20 ng/ml hepato-
cyte growth factor (HGF) (Sigma-Aldrich, St. Louis, MO, USA),
20 ng/ml epithelial growth factor (EGF) (Sigma-Aldrich), and 5%
bovine serum albumin (BSA) (Wako) for 3 days with or with-
out 1mM oleic acid (Sigma-Aldrich), 1mM elaidic acid (Tokyo
Chemical Industry, Tokyo, Japan), or 1mMpalmitic acid (Wako).
Hepatocytes isolated from adult mice by two-step collagenase
digestion (Seglen, 1979) were also cultured under the same condi-
tions used for iHep cells, except that HGF and EGF were omitted.
MDFs were cultured in Dulbecco’s modified Eagle’s medium
containing 10% fetal bovine serum, 2mM L-glutamine (Nacalai
Tesque), penicillin/streptomycin (Nacalai Tesque), and 5% BSA
for 3 days with or without 1mM oleic acid. To induce lipid secre-
tion, iHep cells were cultured in phenol red-free hepato-medium
containing 20 ng/ml HGF, 20 ng/ml EGF, and 5% BSA for 48 h
with or without 1mM oleic acid. The culture medium was then
changed to remove the oleic acid, and the supernatants were
collected at 12, 24, and 36 h after changing the culture medium.
OIL RED O STAINING
Cultured cells were fixed in 10% formalin for 10min at room
temperature, washed with phosphate-buffered saline (PBS), and
treated with 60% isopropanol for 1min at room temperature.
The cells were then incubated with 60% Oil red O (Muto Pure
Chemicals, Tokyo, Japan) in water for 20min at room tem-
perature. After washing with 60% isopropanol for 1min and
additional washing with PBS, the cells were incubated with hema-
toxylin (Muto Pure Chemicals) for 5min.
MEASUREMENT OF TRIGLYCERIDE AND APOLIPOPROTEIN B (APO B)
Cultured cells were washed with PBS, collected using a cell scraper
into a triglyceride assay buffer [5%Triton X-100 (Nacalai Tesque),
1mM EDTA (Nacalai Tesque), and 25mM Tris-HCl pH 7.5], and
lysed by sonication. The triglyceride contents in the cell lysates
and supernatants and the apo B contents in the supernatants
were detected using a Triglyceride Assay Kit (BioAssay Systems,
Hayward, CA, USA) and a Total Human Apo B ELISA Assay
Kit (ALerCHEK Inc., Portland, ME, USA), respectively, according
to the manufacturer’s instructions. The absorbance signals were
measured with a Multiskan FCmicroplate reader (Thermo Fisher
Scientific, Waltham, MA, USA).
ANALYSIS OF THE EFFECTS OF LIPID METABOLISM IMPROVERS
iHep cells were cultured in hepato-medium containing 20 ng/ml
HGF, 20 ng/ml EGF, and 5% BSA for 3 days with or with-
out 1mM oleic acid, 15μM 5-(tetradecyloxy)-2-furoic acid
(TOFA) (Sigma-Aldrich), and 10μM clofibrate (Tokyo Chemical
Industry). Hepatocytes were also cultured under the same condi-
tions used for iHep cells, except that HGF and EGF were omitted.
We added clofibrate to the culture media every day.
STATISTICAL ANALYSIS
Data are shown as mean ± standard deviation (SD), and statisti-
cal significance was analyzed using an unpaired Student’s t-test
or a One-Way ANOVA. P < 0.05 was considered statistically
significant.
STUDY APPROVAL
The experiments were approved by the Kyushu University Animal
Experiment Committee, and the care of the animals was in
accordance with institutional guidelines.
RESULTS
iHEP CELLS CAN SYNTHESIZE LIPIDS FROM A CIS-UNSATURATED
FATTY ACID, SIMILAR TO HEPATOCYTES
In a previous study, we reported a method for the conversion
of MDFs into iHep cells (Sekiya and Suzuki, 2011). In accor-
dance with this method, we generated iHep cells by introducing
Hnf4α and Foxa3 into dermal fibroblasts obtained from adult
mice. As shown in Figure 1A, iHep cells had features of epithe-
lial cells and hepatocytes, including the expression of E-cadherin
and albumin, respectively. iHep cells became attached to each
other through intercellular adhesion molecules, and the size of
the iHep cells was smaller than that of MDFs. To investigate the
function of lipid metabolism in iHep cells, we used iHep cells
that were generated in three independent experiments (n = 3). In
the presence of oleic acid, a cis-unsaturated fatty acid, in the cul-
ture medium, many lipid droplets were observed in the cytoplasm
of iHep cells and primary hepatocytes, but not in the cytoplasm
of MDFs (Figure 1B). Moreover, the amounts of triglyceride in
iHep cells and primary hepatocytes were significantly increased
in cultures with oleic acid (Figure 1C). These data demonstrated
that iHep cells acquired the ability to synthesize lipids from a
cis-unsaturated fatty acid and accumulate these lipids into many
cellular vesicles, similar to hepatocytes, by reprogramming of the
original fate of fibroblasts into the hepatic fate.
iHEP CELLS CAN SYNTHESIZE LIPIDS FROM A TRANS-UNSATURATED
FATTY ACID AND A SATURATED FATTY ACID
In addition to a cis-unsaturated fatty acid, we examined whether
iHep cells could synthesize lipids from a trans-unsaturated fatty
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FIGURE 1 | iHep cells can synthesize lipids from a cis-unsaturated fatty
acid. (A) Morphologies of MDFs and MDF-derived iHep cells.
Co-immunofluorescence staining of albumin and E-cadherin was conducted
for MDFs and iHep cells. DNA was stained with DAPI. (B) iHep cells can
synthesize and store abundant lipids in cultures containing oleic acid, a
cis-unsaturated fatty acid. Phase-contrast images of MDFs, iHep cells, and
primary hepatocytes in cultures without oleic acid are shown. Oil red O
staining was conducted for MDFs, iHep cells, and primary hepatocytes
cultured with (+) or without (−) oleic acid. DNA was stained with hematoxylin.
(C) Quantification of triglyceride contents in iHep cells and primary
hepatocytes cultured with (+) or without (−) oleic acid. We chose three
independent iHep cells for examination. The graphs show the average of three
independent experiments (mean ± SD). ∗P < 0.01, ∗∗P < 0.05 (Student’s
t-test). Scale bars, 50μm.
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acid and a saturated fatty acid, both of which are often present
in foods. iHep cells and primary hepatocytes were each cultured
with elaidic acid, a trans-unsaturated fatty acid, or palmitic acid,
a saturated fatty acid, for 3 days, and then subjected to oil red O
staining to investigate their lipid synthesis and accumulation. The
data showed that many lipid droplets were formed in both types
of cells, and that the sizes of the droplets in cells cultured with
elaidic acid were larger than those in cells cultured with palmitic
acid (Figure 2A). In addition, the amounts of triglyceride in iHep
cells and primary hepatocytes were increased in cultures with
elaidic acid or palmitic acid (Figure 2B). Thus, similar to hepa-
tocytes, iHep cells can synthesize lipids from a trans-unsaturated
fatty acid and a saturated fatty acid, and accumulate these lipids
into many droplets in cells, similar to the case for the culture with
a cis-unsaturated fatty acid.
iHEP CELLS POSSESS THE CAPABILITY FOR LIPID SECRETION
Next, we examined whether iHep cells could secrete lipids to
the culture medium, similar to hepatocytes. To this end, we
maintained iHep cells in culture with oleic acid for 48 h, and
then changed the culture medium to remove the oleic acid. The
supernatants were collected at 12, 24, and 36 h after changing
the culture medium for analysis (Figure 3A). Quantification of
the triglyceride contents showed that the amounts of triglyc-
eride in the supernatants increased after removal of oleic acid
from the culture medium (Figure 3B). In addition to triglyceride,
the amounts of apo B, which is the major protein compo-
nent of triglyceride-rich lipoproteins, in the supernatants also
increased after removal of oleic acid from the culture medium
(Figure 3C). Moreover, the number of lipid droplets in iHep
cells was decreased at 36 h after changing the culture medium,
FIGURE 2 | iHep cells are capable of synthesizing lipids from a
trans-unsaturated fatty acid and a saturated fatty acid. (A) Oil red O
staining was conducted for iHep cells and primary hepatocytes cultured
with elaidic acid, a trans-unsaturated fatty acid, or palmitic acid, a saturated
fatty acid, and without any fatty acids (control). DNA was stained with
hematoxylin. Scale bars, 50μm. (B) Quantification of triglyceride contents
in iHep cells and primary hepatocytes cultured with elaidic acid or palmitic
acid and without any fatty acids (control). The graphs show the average of
three independent experiments (mean ± SD). ∗P < 0.01, ∗∗P < 0.05
(One-Way ANOVA).
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suggesting that the lipids synthesized from oleic acid in iHep cells
were secreted from the cells into the supernatant (Figure 3D).
These data demonstrated that iHep cells possessed the ability to
not only synthesize lipids from fatty acids, but also secrete these
lipids by exocytosis, similar to hepatocytes.
INHIBITION OF LIPID SYNTHESIS IN iHEP CELLS BY LIPID
METABOLISM IMPROVERS
As shown above, iHep cells had the potential to synthesize,
accumulate, and secrete lipids in culture, similar to hepato-
cytes, suggesting that iHep cells could be used in the screening
of lipid metabolism improvers for patients with liver diseases
involving lipid metabolism. Thus, we further examined whether
FIGURE 3 | iHep cells have the ability to secrete triglyceride and apo B.
(A) Schematic diagram of the experimental procedure. iHep cells were
cultured with or without oleic acid for 48 h, and then cultured for 36 h after
changing the culture medium. The supernatants were collected at 12, 24,
and 36 h after changing the culture medium, and the amounts of triglyceride
and apo B in the supernatants were measured. (B,C) Quantification of
triglyceride (B) and apo B (C) contents in the supernatants collected at 12,
24, and 36 h after changing the culture medium. The amounts of triglyceride
and apo B in the supernatants were normalized to the values per 1 × 104
cultured cells. The graphs show the average of three independent
experiments (mean ± SD). ∗P < 0.01, ∗∗P < 0.05 (Student’s t-test). (D) Oil
red O staining was conducted for iHep cells at 0 and 36 h after changing the
culture medium. DNA was stained with hematoxylin. Scale bars, 50μm.
the lipid synthesis in iHep cells could be inhibited by the effects
of well-known lipid metabolism improvers. To this end, we cul-
tured iHep cells with TOFA or clofibrate, both of which are known
to act as lipid metabolism improvers, in addition to oleic acid.
TOFA blocks lipid synthesis by inhibiting acetyl-CoA carboxylase
in the fatty acid biosynthetic pathway, as shown in rat hepatocytes
in vitro (Panek et al., 1977; McCune and Harris, 1979). Clofibrate
is an agonist of peroxisome proliferator-activated receptor α and
stimulates peroxisomal β-oxidation (Scotto et al., 1995; Wheelock
et al., 2007). Both TOFA and clofibrate are used for the treat-
ment of fatty liver diseases in humans. Our data showed that
the amounts of triglyceride in iHep cells and primary hepa-
tocytes were decreased in cultures with oleic acid and TOFA
or clofibrate, indicating that iHep cells could respond to the
lipid metabolism improvers and reduce lipid synthesis, similar
to hepatocytes (Figure 4). Thus, iHep cells could be used for
evaluating the effects of lipid metabolism improvers and screen-
ing of drugs for patients with lipid metabolism disorders, as an
alternative to hepatocytes.
DISCUSSION
In this study, we investigated the potential for lipid metabolism
in iHep cells that were directly induced from MDFs by infec-
tion with a retrovirus expressing Hnf4α and Foxa3. We found
that iHep cells were not only able to synthesize lipids from a cis-
unsaturated fatty acid, but also able to accumulate and secrete the
synthesized lipids, similar to hepatocytes. In addition, iHep cells
were capable of synthesizing lipids from a trans-unsaturated fatty
acid and a saturated fatty acid, as well as from a cis-unsaturated
fatty acid. Moreover, both iHep cells and primary hepatocytes
were capable of responding to the well-known lipid metabolism
improvers TOFA and clofibrate. Thus, it is possible that iHep cells
will also respond to other lipidmetabolism improvers, in addition
to TOFA and clofibrate. Taken together, our data demonstrate
that iHep cells have some of the important functions in hepatic
FIGURE 4 | iHep cells can respond to lipid metabolism improvers. (A,B)
Quantification of triglyceride contents in iHep cells (A) and primary
hepatocytes (B) cultured with or without oleic acid, and supplemented with
or without the well-known lipid metabolism improvers TOFA or clofibrate.
The graphs show the average of three independent experiments (mean ±
SD). ∗P < 0.01 (One-Way ANOVA).
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lipid metabolism and could be useful in the screening of drugs
for patients with lipid metabolism disorders.
In the present study, we measured the amounts of triglyc-
eride to quantify the cellular lipid contents within iHep cells
and primary hepatocytes. However, hepatocytes can also synthe-
size other types of lipid, including cholesterol. In our previous
study, microarray data demonstrated that the expressions of genes
involved in cholesterol metabolism in iHep cells became close to
those in hepatocytes, suggesting that iHep cells are also able to
synthesize cholesterol, similar to hepatocytes (Sekiya and Suzuki,
2011). In addition, iHep cells expressed genes involved in glu-
cose and xenobiotic metabolism (Sekiya and Suzuki, 2011). Thus,
it is possible to speculate that iHep cells possess the poten-
tial for glucose and xenobiotic metabolism, as well as that the
potential for lipid metabolism that was demonstrated in this
study.
Although the amount of triglyceride in iHep cells was less
than that in primary hepatocytes, the function and number of
iHep cells could be maintained in culture, unlike the case for
hepatocytes. Currently, particular cell lines derived from liver
cancer cells, which have some hepatic functions and can be
maintained in culture, are used as alternatives to hepatocytes in
the screening of drugs. Thus, these liver cancer cell lines would
appear to be more useful than iHep cells. However, the nature
of liver cancer cell lines is different from that of normal hep-
atocytes, and it has thus been desirable to identify a new type
of cells that can be maintained in culture with the properties of
normal hepatocytes to examine the pharmacological effects of
drugs. Recently, in addition to iHep cells, hepatocyte-like cells
induced from ES cells and iPS cells have been expected to be
useful in the screening of drugs (Basma et al., 2009; Rashid
et al., 2010; Si-Tayeb et al., 2010; Cayo et al., 2012; Choi et al.,
2013). However, it has remained unclear whether these iHep
cells and stem cell-derived hepatocyte-like cells have the poten-
tial for lipid metabolism, similar to hepatocytes. In this study, we
clearly showed that iHep cells possess the properties of hepato-
cytes in lipid metabolism, by synthesizing lipids from fatty acids,
accumulating the lipids in cellular vesicles, secreting the lipids
into the culture medium, and responding to lipid metabolism
improvers, even after expansion in culture for a relatively long
period. Thus, iHep cells will be useful in the screening of drugs
for patients with liver diseases involving lipid metabolism, as an
alternative to hepatocytes and liver cancer cell lines. Moreover,
it is expected that iHep cells will be useful in basic research to
analyze the mechanisms underlying hereditary lipid metabolism
disorders.
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